Kyverna Therapeutics
KYTX
Performance
About Kyverna Therapeutics
Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies to treat autoimmune diseases. Its lead CAR T-cell therapy candidate mivocabtagene (miv-cel, KYV-101) is advancing through multiple phase trials in rheumatology and neurology, including lupus nephritis, stiff person syndrome, multiple sclerosis, myasthenia gravis, and systemic sclerosis, with trials conducted in the United States and Europe. The company pursues autologous and allogeneic CAR T-cell platforms aimed at deep B cell depletion and long-term immune reset for patients with autoimmune conditions. Kyverna emphasizes patient-centric clinical development and global collaboration to bring transformative cell therapies to patients living with autoimmune diseases.
Recent News
AAN 2026: J&J, Kyverna, Capricor and Praxis Showcase Practice-Changing Data
An Experimental New Drug for Stiff Person Syndrome Restores Mobility
CAR-T Therapy for Stiff Person Syndrome Nears Approval
STAT+: Kyverna Therapeutics Plans to Submit Cell Therapy for Stiff Person Syndrome for FDA Approval
From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era
JPM Day 3: Rare Disease in the Spotlight
Pursuing a Rare Autoimmune Disease Accelerated Kyverna’s Path to BLA
Recent Deals
No recent deals for this company.